Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Zydus stated that, unlike existing treatment options that require patients to purchase multiple single-dose pens during dose titration, it is offering a reusable multi-dose pen device. This innovation allows patients and clinicians to select and administer different dose strengths from a single pen, which the company claims will improve adherence, enhance convenience, and reduce overall treatment costs. The semaglutide injection will be available in a 15 mg/3 ml cartridge and will be manufactured at Zydus Biotech Park in Ahmedabad. The company said the average monthly cost of therapy is expected to be around Rs 2,200.
Zydus also highlighted that diabetes and obesity are major public health challenges in India. Citing the International Diabetes Federation, it noted that 8.9 crore adults in India are living with diabetes, representing 10.5% of the adult population. The company further pointed out a sharp rise in obesity prevalence among adults, increasing by 91% in women and 146% in men, underscoring the growing burden of lifestyle-related diseases in the country.
Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.
The company's consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.
Shares of Zydus Lifesciences rose 1.63% to settle at Rs 890.60 on the BSE.
Powered by Capital Market - Live News